Patricia K. Coyle, MD

Patricia K. Coyle, MD - recipient of the 2026 Giants of MS June Harper Visionary Award and medical honoree at National MS Society’s 2022 Runway for MS Fashion Show.

• Multiple sclerosis
• NMOSD
• Lyme Disease

• Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses
  Arnaboldi PM, Becker J, Nath A, Coyle PK, et al. Brain. 2026 Jun;149(6):1842-1859.
   
• Special Edition: Therapeutic advances in multiple sclerosis
  Coyle PK. Neurotherapeutics. 2025 Jul; 22(4):e00697.
   
• Impact of sex on multiple sclerosis therapy
  Coyle PK. Neurotherapeutics. 2025 Jul;22(4):e00620.
   
• How Do I Approach the Evaluation and Treatment of Early Lyme Disease?
  Schutzer SE, Coyle PK. NEJM Evid. 2024 Aug;3(8):EVIDccon2300131.
   
• SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population
  Hadidchi R, Wang SH, Rezko D, Henry S, Coyle PK, Duong TQ. Mult Scler Relat Disord. 2024 Jun;86:105613.
   
• Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review
  Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE. Ann Clin Transl Neurol. 2024 Apr;11(4):842-855.
   
• Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
  Freedman MS, Coyle PK, Hellwig K, et al. Neurol Ther. 2024 Apr;13(2):283-322.
   
• Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium
  Jakimovski D, Kavak KS, Coyle PK, et al. J Neurol. 2024 Feb;27(2):711-722.
   
• Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study
  Jakimovski D, Kavak KS, Zakalik K, McGraw C, Gottesman M, Coyle PK, et al. J Neurol Sci. 2023 Dec 15;455:122781.
   
• Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review
  De Lury AD, Bisulca JA, Lee JS, Altaf MD, Coyle PK, Duong TQ. J Neurol Sci. 2023 Oct 15;453:120816.
   
• Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical
  Coyle PK. Neurotherapeutics. 2023 Oct;20(6):1692-1693.
   
• Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey
  Tumani H, Coyle PK, Carcamo C, et al. Mult Scler J Exp Transl Clin. 2023 Sept 13;9(3):20552173231198588.
   
• Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic
  Coyle PK, Gorritz M, Wade RL, et al. Mult Scler Relat Disord. 2023 Oct:78:104881. 
   
• Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study
  Hua LH, Bar-Or A, Cohan SL, Lublin FD, Coyle PK, et al. Mult Scler Relat Disord. 2023 Jul:75:104766.
   
• High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis
  Freeman L, Longbrake EE, Coyle PK, et al. CNS Drugs. 2022 Dec;36(12):1285-1299.
   

List of Publications - Patricia K. Coyle